RGPX · As filed with the SEC

Regenerex Pharma cash flow statement, by quarter

The statement as Regenerex Pharma presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.

STATEMENTS OF CASH FLOWS · USD

USD	Q2 FY25^† 3 months ended Sep 30, 2025	Q1 FY24 3 months ended Jun 30, 2025	Q4 FY24^† 3 months ended Mar 31, 2025	Q3 FY24^† 3 months ended Dec 31, 2024
Cash Flows from Operating Activities:
Net Income (Loss)	(814,012)^†	(663,584)	(1,410,385)^†	(314,524)^†
Adjustments to reconcile net loss to cash flows used in operating activities:
Depreciation Expense	1,157^†	1,259	426^†	643^†
Foreign currency adjustment	539^†	6,092	17,294^†	(24,000)^†
Stock-Based Compensation Expense	177,867^†	257,133	57,894^†	17,973^†
Non-cash extension fee to Greenwich Resources	—	—	—	0^†
Net Cash from Operating Activities	—	—	(3,349)^†	(3,348)^†
Amortization of ROU assets, net of liabilities	(3,348)^†	(13,348)	—	—
Changes in operating assets and liabilities:
Prepaid expenses	(16,520)^†	(19,900)	300^†	891^†
Accounts payable	47,481^†	(26,405)	66,608^†	51,221^†
Accrued compensation	(54,593)^†	20,250	40,118^†	96,885^†
Other accrued liabilities	142,074^†	(39,440)	(53,606)^†	15,546^†
Net Cash from Operating Activities	(519,355)^†	(477,943)	(1,284,700)^†	(158,713)^†
Proceeds from Debt Issuance	—	—	3,805^†	—
Repayment of notes payable to related parties	(87,498)^†	(17,652)	—	—
Affiliated Entity	—	—	568,920^†	—
Proceeds from Stock Issuance	485,000^†	15,000	2,250,000^†	0^†
Net cash provided by financing activities	397,502^†	(2,652)	1,938,615^†	158,757^†
Net Change in Cash	(160,771)^†	(480,595)	652,687^†	44^†
Cash and cash equivalents, beginning of period	172,430	653,025	338	294
Cash and cash equivalents, end of period	11,659	172,430	653,025	338
Accrued interest converted into note payable to shareholder	11,688^†	11,779	43,511^†	12,059^†
Accrued interest converted into note payable to related parties	6,420^†	7,211	11,469^†	7,686^†
Operating lease, ROU asset and liabilities	—	—	0^†	—
Note payable for interest expense	—	—	—	0^†
Non-Cash Investing and Financing	41,613^†	18,990	—	—

† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.

As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.